Skip to content
Care, coaching and clear next steps.
I start here!
Menu
← Back to Pephelp

A peptide list,
with a clearer picture.

A searchable peptide chart with 12 molecules, from semaglutide to BPC-157. Compare brand names, documented effects and US status, with the context that matters.

YOUR REFERENCE, WITHOUT THE RABBIT HOLE

12 peptides at a glance.

Explore by name or topic. Colored tags group the questions people ask; each entry explains what the research has actually shown.

Evidence last checked against peer-reviewed trials and current FDA labels. Clinical review pending.

Showing 12 peptides

Peptide molecules, documented outcomes, evidence types and US regulatory status. Evidence type does not imply benefit.
PEPTIDE / BRANDTOPIC / DOCUMENTED EFFECTRESEARCH EVIDENCE ⓘUS STATUSRead details
01
Wegovy · Ozempic · RybelsusGLP-1 receptor agonist
  • Weight loss
  • Weight loss

Weight reduction in adults with overweight or obesity.

Clinical trialsLarge randomized trialsFDA-approved productsFor specific indications
02
Zepbound · MounjaroGIP / GLP-1 receptor agonist
  • Weight loss
  • Weight loss

Weight reduction in adults with overweight or obesity.

Clinical trialsLarge randomized trialsFDA-approved productsFor specific indications
03
Saxenda · VictozaGLP-1 receptor agonist
  • Weight loss
  • Weight loss

Weight reduction alongside diet and physical activity.

Clinical trialsLarge randomized trialsFDA-approved productsFor specific indications
04
Egrifta WR · Egrifta SVGrowth hormone–releasing hormone analogue
  • Body composition
  • Body composition

Less excess abdominal fat in adults with HIV-associated lipodystrophy.

Clinical trialsIndication-specific clinical evidenceFDA-approved productsFor specific indications
05
No approved brandGIP / GLP-1 / glucagon receptor agonist
  • Weight loss
  • Weight loss

Weight and blood-glucose improvements in clinical trials.

Clinical trialsPhase 3 published · September 2026InvestigationalSee context & limitations
06
No FDA-approved brandSynthetic 15-amino-acid peptide
  • Recovery
  • Recovery

Small human reports of symptom improvement; tissue repair remains unproven.

Limited human dataSmall, mostly uncontrolled human reportsNo FDA-approved drugSee context & limitations
07
No FDA-approved brandAc-LKKTETQ · thymosin β4 fragment
  • Recovery
  • Recovery

No established human clinical benefit for this fragment.

Preclinical / no direct trialNo direct human clinical data in FDA reviewNo FDA-approved drugSee context & limitations
08
Copper tripeptide-1 in cosmetic formulasCopper complex of glycyl-histidyl-lysine
  • Skin health
  • Skin health

Limited topical skin evidence; injectable benefits unestablished.

Limited human dataSmall, formulation-specific studiesCosmetic ingredientTopical use ≠ injectable evidence
09
Thymalfasin · also known as Zadaxin outside the US28-amino-acid immunomodulatory peptide
  • Immune health
  • Immune health

No significant survival benefit in a large sepsis trial.

Clinical trialsPhase 3 trial · primary result negativeNo FDA-approved drugSee context & limitations
10
No FDA-approved brandAla-Glu-Asp-Gly · synthetic tetrapeptide
  • Healthy aging
  • Sleep
  • Healthy aging
  • Sleep

Exploratory biomarker changes; longer human lifespan unproven.

Limited human dataCell studies and limited human biomarker dataNo FDA-approved drugSee context & limitations
11
No FDA-approved brandLong-acting GHRH analogue with DAC
  • Muscle & strength
  • Sleep
  • Muscle & strength
  • Sleep

Increased GH and IGF-1 concentrations in healthy adults.

Limited human dataShort randomized biomarker trialsNo FDA-approved drugSee context & limitations
12
No FDA-approved brandGhrelin receptor agonist / GH secretagogue
  • Muscle & strength
  • Sleep
  • Muscle & strength
  • Sleep

No significant improvement in the primary postoperative bowel-recovery outcome.

Limited human dataHuman trial in a different clinical settingNo FDA-approved drugSee context & limitations

A topic is not a treatment claim. “Clinical trials” describes the research, including negative results. Approval applies to specific products and indications.

US status · Checked November 5, 2026

How this list is different

Each entry separates the documented outcome, the limits of the research and linked sources; when direct human evidence is missing, we say so. Approval belongs to a specific product and indication, not every preparation of a molecule. This is an educational reference, with clinical review pending.

Your next step with Pephelp

Let’s put your questions first.

The evidence is a place to start. Our short quiz helps you connect it to your goals, priorities and next conversation.

Find my next step

US care · Clinical review before treatment

Compare plans and prices

CURIOSITY, WITH CONTEXT

A better starting point.
Not the last word.

Peptides are a diverse family of molecules. A medicine with large clinical trials and an experimental compound can share a headline. They shouldn’t share an assumption.

Read our evidence key
01 /

Look at what was measured.

A change in a hormone or a cell culture isn’t the same as a meaningful benefit in a person.

02 /

The details change the answer.

The molecule, formulation, route and patient population need to match the claim.

03 /

Make room for “we don’t know.”

Small studies can offer clues. Missing data cannot promise safety. Bring the evidence to a qualified clinician.

HOW TO READ THIS GUIDE

Clinical trials

Controlled human research examining a clinical outcome. Results can be positive, mixed or negative; this is not a formal certainty score.

Limited human data

Small reports, early trials or biomarker studies. Evidence may not demonstrate the benefits commonly claimed.

Preclinical / no direct trial

Laboratory or animal work, or no direct human trial identified for the exact molecule. Human benefit remains unestablished.

First edition · A curated reference, not an exhaustive or systematic review. Prepared by Pephelp from linked sources and our research notes. Clinical review is pending. Read our editorial process or explore the articles. US status is a dated snapshot; other countries differ. Educational information, not a prescription or personal treatment recommendation.

PEPHELP / FIELD NOTE

Metabolic health

Semaglutide

GLP-1 receptor agonist

Wegovy · Ozempic · Rybelsus

  • Weight loss

Topics to explore. See the findings and limitations below.

Clinical trialsFDA-approved products

What the research found

In STEP 1, 1,961 adults without diabetes were randomized. Average weight change at 68 weeks was −14.9% with semaglutide versus −2.4% with placebo; both groups received lifestyle support. In SELECT, 17,604 adults with cardiovascular disease and overweight or obesity but no diabetes were randomized: cardiovascular death, heart attack or stroke occurred in 6.5% with semaglutide versus 8.0% with placebo over a mean of 39.8 months. A Nature Medicine analysis of the same trial reported mean weight change of −10.2% versus −1.5% at 208 weeks. In OASIS 4, a once-daily 25 mg tablet produced −13.6% versus −2.2% with placebo at 64 weeks.

Keep the context

Each result applies to the studied formulation, dose and population. SELECT enrolled people with existing cardiovascular disease, so its heart findings do not transfer to everyone. None of these trials establishes that every semaglutide product or compounded preparation has the same evidence.

Approval & availability

FDA-approved products have different formulations and indications. Wegovy includes weight management for eligible patients, and its current label covers both an injection and a tablet; Ozempic and Rybelsus are diabetes brands. Consult the exact current product label.

Safety context

Gastrointestinal effects are common. Product labels include important contraindications and a boxed warning about thyroid C-cell tumors. Individual suitability requires a prescriber.

Understand your options

How to check product approval · Weight-management options · Semaglutide vs. tirzepatide

Go to the source

Peer-reviewed studySTEP 1 · NEJM, 2021 (opens in a new tab)Peer-reviewed studySELECT cardiovascular outcomes · NEJM, 2023 (opens in a new tab)Peer-reviewed studySELECT 4-year weight analysis · Nature Medicine, 2024 (opens in a new tab)Peer-reviewed studyOASIS 4 oral semaglutide 25 mg · NEJM, 2025 (opens in a new tab)Official labelWegovy · current prescribing information (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Metabolic health

Tirzepatide

GIP / GLP-1 receptor agonist

Zepbound · Mounjaro

  • Weight loss

Topics to explore. See the findings and limitations below.

Clinical trialsFDA-approved products

What the research found

SURMOUNT-1 randomized 2,539 adults without diabetes. At 72 weeks, average weight changes across tirzepatide groups were −15.0% to −20.9%, versus −3.1% with placebo. In SURMOUNT-5, a head-to-head trial in 751 adults, mean weight change at 72 weeks was −20.2% with tirzepatide versus −13.7% with semaglutide. SURMOUNT-3, published in Nature Medicine, found a further −18.4% versus +2.5% with placebo in people who had already lost weight through an intensive lifestyle program. In SURMOUNT-OSA, sleep-apnea events fell by 25.3 per hour versus 5.3 with placebo in adults not using PAP.

Keep the context

SURMOUNT-5 was open-label, sponsored by the maker of tirzepatide, and compared maximum tolerated doses; other cross-trial comparisons cannot rank medicines fairly. These results are not a promise of individual weight loss.

Approval & availability

Zepbound has FDA-approved weight-management and obstructive-sleep-apnea indications for eligible patients. Mounjaro is a diabetes brand. Approval belongs to the specific product and indication.

Safety context

Gastrointestinal effects are common. The label includes a thyroid C-cell tumor boxed warning and other contraindications and precautions.

Understand your options

How to check product approval · Weight-management options · Semaglutide vs. tirzepatide

Go to the source

Peer-reviewed studySURMOUNT-1 · NEJM, 2022 (opens in a new tab)Peer-reviewed studySURMOUNT-5 vs semaglutide · NEJM, 2025 (opens in a new tab)Peer-reviewed studySURMOUNT-3 · Nature Medicine, 2023 (opens in a new tab)Peer-reviewed studySURMOUNT-OSA · NEJM, 2024 (opens in a new tab)Official labelZepbound · prescribing information (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Metabolic health

Liraglutide

GLP-1 receptor agonist

Saxenda · Victoza

  • Weight loss

Topics to explore. See the findings and limitations below.

Clinical trialsFDA-approved products

What the research found

The SCALE trial randomized 3,731 adults without diabetes. Mean weight loss at 56 weeks was 8.4 kg with liraglutide versus 2.8 kg with placebo, alongside lifestyle counseling.

Keep the context

Results are specific to the studied weight-management formulation and population. Diabetes and weight-management brands are not interchangeable recommendations.

Approval & availability

Saxenda is an FDA-approved weight-management product for eligible patients; Victoza is a diabetes brand. This guide highlights selected uses, not every indication.

Safety context

Nausea and diarrhea were frequent in the trial. The label contains a thyroid C-cell tumor boxed warning and other prescribing restrictions.

Understand your options

How to check product approval · Weight-management options

Go to the source

Peer-reviewed studySCALE · NEJM, 2015 (opens in a new tab)Official labelSaxenda · prescribing information (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Hormone research

Tesamorelin

Growth hormone–releasing hormone analogue

Egrifta WR · Egrifta SV

  • Body composition

Topics to explore. See the findings and limitations below.

Clinical trialsFDA-approved products

What the research found

In a 26-week trial, 412 adults with HIV and abdominal fat accumulation were randomized; visceral fat decreased 15.2% with tesamorelin and increased 5.0% with placebo. A 2025 phase 2 trial found no significant cognitive benefit despite a smaller waist.

Keep the context

This is not an approval for general weight loss, bodybuilding or anti-aging. The label states that the medicine is not indicated for weight-loss management.

Approval & availability

FDA-approved Egrifta formulations are prescribed for excess abdominal fat in adults with HIV and lipodystrophy. Formulations have different preparation instructions and are not interchangeable.

Safety context

Important issues include elevated IGF-1, glucose intolerance, fluid retention and malignancy-related contraindications. Long-term cardiovascular safety is not established.

Understand your options

How to check product approval

Go to the source

Peer-reviewed studyPhase 3 visceral-fat trial · NEJM, 2007 (opens in a new tab)Peer-reviewed studyNeurocognitive trial · J Infect Dis, 2025 (opens in a new tab)Official labelEgrifta WR · trials, indication and safety (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Metabolic health

Retatrutide

GIP / GLP-1 / glucagon receptor agonist

No approved brand

  • Weight loss

Topics to explore. See the findings and limitations below.

Clinical trialsInvestigational

What the research found

TRIUMPH-1 randomized 2,339 adults with obesity without diabetes. At 80 weeks, mean weight change was −17.6% (4 mg), −23.7% (9 mg) and −25.0% (12 mg) versus −3.9% with placebo. TRIUMPH-2 randomized 1,152 adults with overweight or obesity and type 2 diabetes. At 80 weeks, mean weight change was −11.9% to −18.8% across retatrutide groups versus −5.1% with placebo. A phase 2a substudy in Nature Medicine reported liver-fat reductions of 43% to 82% at 24 weeks in 98 participants with fatty liver disease.

Keep the context

Phase 3 results strengthen the evidence but are not marketing approval. Liver-fat change is an imaging measure, not proof of fewer liver complications. Trial findings do not apply to products sold online under the same name.

Approval & availability

Investigational; no FDA-approved retatrutide product. Trial findings do not validate products sold online under the same name.

Safety context

Gastrointestinal adverse events were common; hypotension and altered sensation were more frequent than with placebo. The safety profile remains under evaluation.

Go to the source

Peer-reviewed studyTRIUMPH-1 · NEJM, 2026 (opens in a new tab)Peer-reviewed studyTRIUMPH-2 · The Lancet, 2026 (opens in a new tab)Peer-reviewed studyLiver-fat substudy · Nature Medicine, 2024 (opens in a new tab)Regulatory sourceFDA · unapproved GLP-1 medicines (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Recovery research

BPC-157

Synthetic 15-amino-acid peptide

No FDA-approved brand

  • Recovery

Topics to explore. See the findings and limitations below.

Limited human dataNo FDA-approved drug

What the research found

A retrospective knee-pain report interviewed 16 people; 14 reported improvement. Four had also received thymosin beta-4. A 2026 systematic review found three human studies with 30 participants in total, all of poor methodological quality, and rated the certainty of evidence very low.

Keep the context

No control group or objective demonstration of tendon/cartilage repair in that report. Animal healing findings and short safety observations cannot establish effective, safe human treatment.

Approval & availability

No FDA-approved BPC-157 drug. FDA reviewed the substance for compounding in 2026; a compounding discussion is not drug approval.

Safety context

Human safety information is limited, especially for long-term use. Identity, purity and route matter; absence of reported events in a tiny sample does not establish safety.

Go to the source

Peer-reviewed studyKnee-pain case series · 2021 (opens in a new tab)Peer-reviewed studySystematic review of human evidence · Acta Orthop Belg, 2026 (opens in a new tab)Peer-reviewed studyOrthopaedic evidence review · JAAOS, 2026 (opens in a new tab)Regulatory assessmentFDA · BPC-157 evidence assessment, 2026 (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Recovery research

TB-500

Ac-LKKTETQ · thymosin β4 fragment

No FDA-approved brand

  • Recovery

Topics to explore. See the findings and limitations below.

Preclinical / no direct trialNo FDA-approved drug

What the research found

FDA’s 2026 assessment found no human clinical data for the seven-amino-acid fragment it evaluated as TB-500. A 2026 orthopaedic review likewise found no controlled human musculoskeletal evidence and noted that TB-500 is often conflated with full-length thymosin beta-4.

Keep the context

Full-length thymosin beta-4 has 43 amino acids and is a different molecule. Its eye-drop trials do not establish tendon healing or safety for injectable TB-500. Sellers may use the names inconsistently.

Approval & availability

No FDA-approved TB-500 drug. This entry describes the acetylated fragment assessed by FDA, not all products sold under the name.

Safety context

Human benefit and safety are not established for this fragment. The identity of a research product cannot be inferred from a marketing name.

Go to the source

Regulatory assessmentFDA · TB-500 assessment, 2026 (opens in a new tab)Peer-reviewed studyOrthopaedic evidence review · JAAOS, 2026 (opens in a new tab)Peer-reviewed studyRelated molecule only: full-length Tβ4 eye-drop trial (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Skin & cosmetics

GHK-Cu

Copper complex of glycyl-histidyl-lysine

Copper tripeptide-1 in cosmetic formulas

  • Skin health

Topics to explore. See the findings and limitations below.

Limited human dataCosmetic ingredient

What the research found

In a randomized study after CO₂ laser resurfacing, 13 participants completed follow-up. Objective skin measures did not show an advantage, although subjective satisfaction was higher.

Keep the context

This small study does not settle every cosmetic use. Evidence from a topical formula cannot be transferred to injections, hair regrowth or systemic anti-aging.

Approval & availability

Used as a cosmetic ingredient. Cosmetic sale is not FDA approval as a drug, and does not establish an injectable medicine’s status or safety.

Safety context

Formulation and route are central. Topical tolerability is not evidence that injection is safe; injectable clinical benefits have not been established here.

Go to the source

Peer-reviewed studyTopical copper tripeptide trial · 2006 (opens in a new tab)Regulatory sourceFDA · cosmetics and approval (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Immune research

Thymosin α1

28-amino-acid immunomodulatory peptide

Thymalfasin · also known as Zadaxin outside the US

  • Immune health

Topics to explore. See the findings and limitations below.

Clinical trialsNo FDA-approved drug

What the research found

TESTS randomized 1,106 patients with sepsis and analyzed 1,089. Thymosin α1 did not significantly reduce 28-day mortality compared with placebo.

Keep the context

A plausible immune mechanism is not proof of infection prevention in healthy people. The negative primary result should not be hidden behind secondary or subgroup findings.

Approval & availability

No FDA-approved thymosin α1 drug. It is not Rethymic, the thymus-tissue product used for congenital athymia. Approval and availability outside the US vary.

Safety context

Use in clinical research does not establish safety or efficacy for preventive wellness. Patient population and concomitant treatments matter.

Go to the source

Peer-reviewed studyTESTS · BMJ, 2025 (opens in a new tab)Peer-reviewed studyTESTS · published correction (opens in a new tab)Regulatory sourceFDA · thymosin alpha-1 approval clarification (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Longevity research

Epitalon

Ala-Glu-Asp-Gly · synthetic tetrapeptide

No FDA-approved brand

  • Healthy aging
  • Sleep

Topics to explore. See the findings and limitations below.

Limited human dataNo FDA-approved drug

What the research found

A small shift-worker study examined melatonin-related markers after sublingual AEDG. Telomerase findings come from cultured cells, not a trial showing longer life in people; a 2025 cell-line study reported telomere lengthening in normal cells and, through a different mechanism, in breast-cancer cell lines.

Keep the context

A changed biomarker is not demonstrated improvement in sleep, lifespan or disease outcomes. Epitalon is distinct from epithalamin extract; route and identity must match the study.

Approval & availability

No FDA-approved epitalon drug. FDA’s 2026 assessment evaluates evidence for proposed compounding uses; it is not an approval.

Safety context

The available data do not establish long-term safety or the safety of injectable use for longevity.

Go to the source

Peer-reviewed studyShift-worker biomarker study · 2020 (opens in a new tab)Peer-reviewed studyTelomere cell-line study · Biogerontology, 2025 (opens in a new tab)Regulatory assessmentFDA · epitalon assessment, 2026 (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Hormone research

CJC-1295

Long-acting GHRH analogue with DAC

No FDA-approved brand

  • Muscle & strength
  • Sleep

Topics to explore. See the findings and limitations below.

Limited human dataNo FDA-approved drug

What the research found

Two short placebo-controlled trials demonstrated sustained increases in growth hormone and IGF-1 after the studied long-acting CJC-1295 formulation.

Keep the context

Higher hormone levels are not proof of better sleep, strength, recovery or longevity. Products described as “CJC without DAC” should not inherit evidence for this long-acting formulation.

Approval & availability

No FDA-approved CJC-1295 drug. This entry concerns the long-acting molecule studied with its drug-affinity complex (DAC).

Safety context

Short trials cannot establish long-term safety. FDA has identified safety concerns in its assessment of CJC-1295, including cardiovascular reactions.

Go to the source

Peer-reviewed studyCJC-1295 randomized trials · JCEM, 2006 (opens in a new tab)Regulatory assessmentFDA · CJC-1295 evidence assessment, 2024 (opens in a new tab)

Checked November 5, 2026
Clinical review pending

PEPHELP / FIELD NOTE

Hormone research

Ipamorelin

Ghrelin receptor agonist / GH secretagogue

No FDA-approved brand

  • Muscle & strength
  • Sleep

Topics to explore. See the findings and limitations below.

Limited human dataNo FDA-approved drug

What the research found

A randomized phase 2 trial analyzed 114 surgical patients. Median time to tolerating a meal was 25.3 hours with intravenous ipamorelin versus 32.6 hours with placebo; the difference was not statistically significant.

Keep the context

That route, population and outcome cannot establish better sleep, muscle gain or recovery from subcutaneous use, including combinations with CJC-1295.

Approval & availability

No FDA-approved ipamorelin drug. FDA flags injectable-compounding safety concerns and gaps in data for other routes.

Safety context

FDA notes serious events, including deaths, in intravenous clinical research; that observation alone does not establish causation. Safety for other injectable uses remains uncertain.

Go to the source

Peer-reviewed studyPostoperative ileus trial · 2014 (opens in a new tab)Regulatory assessmentFDA · ipamorelin assessment, 2024 (opens in a new tab)Regulatory sourceFDA · compounding safety information (opens in a new tab)

Checked November 5, 2026
Clinical review pending

Share this guide

Copy the link below. It includes your current filters and open peptide.